Filing Details

Accession Number:
0001213900-19-019180
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-27 16:16:49
Reporting Period:
2019-09-27
Accepted Time:
2019-09-27 16:16:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1506251 Citius Pharmaceuticals Inc. CTXR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1463414 L Leonard Mazur C/O Citius Pharmaceuticals, Inc.
11 Commerce Drive, 1St Floor
Cranford NJ 07016
Executive Chairman Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-27 2,234,700 $0.90 10,255,343 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant to Purchase Common Stock Acquisiton 2019-09-27 2,234,700 $0.00 2,234,700 $0.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,234,700 2024-09-27 No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Options to Purchase Common Stock $3.45 2027-09-13 40,000 40,000 Direct
Common Stock Warrant to Purchase Common Stock $6.15 2019-06-12 19,614 19,614 Direct
Common Stock Warrant to Purchase Common Stock $9.90 2019-09-30 3,171 3,171 Direct
Common Stock Warrant to Purchase Common Stock $9.90 2020-01-08 4,984 4,984 Direct
Common Stock Warrant to Purchase Common Stock $7.50 2020-08-18 35,211 35,211 Direct
Common Stock Warrant to Purchase Common Stock $7.50 2020-11-02 20,783 20,783 Direct
Common Stock Warrant to Purchase Common Stock $7.50 2020-11-20 20,664 20,664 Direct
Common Stock Warrant to Purchase Common Stock $7.50 2021-01-08 13,679 13,679 Direct
Common Stock Warrant to Purchase Common Stock $7.50 2021-03-14 4,210 4,210 Direct
Common Stock Warrant to Purchase Common Stock $6.15 2021-03-15 18,106 18,106 Direct
Common Stock Warrant to Purchase Common Stock $4.13 2022-08-08 421,400 421,400 Direct
Common Stock Warrant to Purchase Common Stock $4.13 2022-08-08 11,000 11,000 Direct
Common Stock Options to Purchase Common Stock $6.75 2024-09-12 220,000 220,000 Direct
Common Stock Warrant to Purchase Common Stock $4.63 2023-06-19 106,553 106,553 Direct
Common Stock Warrant to Purchase Common Stock $2.86 2023-09-29 167,504 167,504 Direct
Common Stock Warrant to Purchase Common Stock $1.15 2023-08-14 3,137,255 3,137,255 Direct
Common Stock Options to Purchase Common Stock $1.62 2028-09-04 150,000 150,000 Direct
Common Stock Warrant to Purchase Common Stock $1.42 2021-04-05 1,165,048 1,615,048 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2027-09-13 40,000 40,000 Direct
2019-06-12 19,614 19,614 Direct
2019-09-30 3,171 3,171 Direct
2020-01-08 4,984 4,984 Direct
2020-08-18 35,211 35,211 Direct
2020-11-02 20,783 20,783 Direct
2020-11-20 20,664 20,664 Direct
2021-01-08 13,679 13,679 Direct
2021-03-14 4,210 4,210 Direct
2021-03-15 18,106 18,106 Direct
2022-08-08 421,400 421,400 Direct
2022-08-08 11,000 11,000 Direct
2024-09-12 220,000 220,000 Direct
2023-06-19 106,553 106,553 Direct
2023-09-29 167,504 167,504 Direct
2023-08-14 3,137,255 3,137,255 Direct
2028-09-04 150,000 150,000 Direct
2021-04-05 1,165,048 1,615,048 Direct
Footnotes
  1. One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest, provided the Reporting Person continues to serve as a member of the Company's Board of Directors as of each such vesting date.
  2. The warrant is fully vested and exercisable immediately.
  3. The option vested as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017.
  4. The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.
  5. One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.